Colorado – June 23, 2020 – Cooley advised ArcherDX on its agreement to combine with Invitae in a transaction valued at $1.4 billion – creating a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. Partners Laura Medina, Steve Tonsfeldt, Brent Fassett and Charity Williams led the Cooley team advising ArcherDX.
The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and services available. Integrating germline testing, tumor profiling and liquid biopsy technologies and services in a single platform will enable precision approaches from diagnostic testing to therapy optimization and monitoring, expanding access to best-in-class personalized oncology.
"ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care,” Jason Myers, CEO and co-founder of ArcherDX, said in a statement. “We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value.”
Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae’s common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae’s common stock payable in connection with the achievement of certain milestones.
ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.